• Previous evidence from placebo-controlled trials demonstrated that montelukast is an effective preventer medication in children with persistent asthma.
   
• Newer comparative studies suggest that the main roles for montelukast are as an alternative to low-dose inhaled corticosteroids (ICS) or cromones in children with mild persistent asthma or frequent intermittent asthma.
   
• Emerging additional roles for montelukast include protection against viral-induced wheeze in children with intermittent asthma, when given either as continual therapy or short courses in response to the onset of respiratory tract infections.
   
• There is accumulating evidence to support the use of montelukast to protect against exercise-induced bronchoconstriction in children.

Content Updated June 2007